|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:address
|
Plot No. 2, Maitrivihar, Ameerpet, Hyderabad, Telangana, India
|
|
gptkbp:auditedBy
|
gptkb:Deloitte_Haskins_&_Sells_LLP
|
|
gptkbp:corporateOffice
|
gptkb:Hyderabad,_India
|
|
gptkbp:exportedTo
|
gptkb:Africa
gptkb:Asia
gptkb:Australia
gptkb:Europe
gptkb:United_States
|
|
gptkbp:foundedIn
|
1986
|
|
gptkbp:founder
|
gptkb:K._Nityananda_Reddy
gptkb:P._V._Ramprasad_Reddy
|
|
gptkbp:headquartersLocation
|
gptkb:Hyderabad
gptkb:India
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Aurobindo Pharma Limited
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:ISIN
|
INE406A01037
|
|
gptkbp:keyPerson
|
gptkb:K._Nityananda_Reddy
gptkb:P._V._Ramprasad_Reddy
Shivprasad Reddy
|
|
gptkbp:listedOn
|
gptkb:NSE
BSE
|
|
gptkbp:manufacturingFacilities
|
gptkb:Brazil
gptkb:China
gptkb:India
gptkb:Malta
gptkb:Poland
gptkb:Portugal
gptkb:USA
|
|
gptkbp:market
|
Global
|
|
gptkbp:numberOfEmployees
|
2023
~23,000 (2023)
|
|
gptkbp:parentCompany
|
Aurobindo Pharma Group
|
|
gptkbp:products
|
Active pharmaceutical ingredients
Generic pharmaceuticals
|
|
gptkbp:revenue
|
INR 24,774 crore (FY 2022-23)
|
|
gptkbp:stockSymbol
|
gptkb:AUROPHARMA
|
|
gptkbp:subsidiary
|
Aurobindo Pharma USA Inc.
Eugia Pharma Specialities Limited
|
|
gptkbp:therapeuticArea
|
gptkb:Central_nervous_system
gptkb:Antibiotics
Oncology
Dermatology
Gastroenterology
Cardiovascular
Respiratory
Anti-allergics
Anti-diabetics
Anti-retrovirals
|
|
gptkbp:website
|
https://www.aurobindo.com/
|
|
gptkbp:bfsParent
|
gptkb:Aurobindo_Pharma
|
|
gptkbp:bfsLayer
|
6
|